NBIX — Neurocrine Biosciences Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $13.53bn
- $2.86bn
Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates
U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals
Brief: Neurocrine Biosciences Appoints Mike Sibley As Senior Vice President, General Manager Of Neuropsychiatry Franchise
U.S. RESEARCH ROUNDUP- Axos Financial, Vistra, Williams-Sonoma
Neurocrine Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Neurocrine Q2 adjusted EPS beats estimates
Brief: Neurocrine Biosciences Begins Phase 1 Study of NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Brief: Neurocrine Biosciences Shares New Post-Hoc Data
Brief: Neurocrine Biosciences Appoints Lewis Choi As Chief Information Officer
Brief: Neurocrine Reports Late Stage Data Of Crenessity
U.S. RESEARCH ROUNDUP-American Tower, GoDaddy, Labcorp
Neurocrine Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Neurocrine Biosciences Q1 Adjusted EPS USD 0.7 Vs. IBES Estimate USD 0.54
Brief: Neurocrine Biosciences Initiates Phase 3 Registrational Program For NBI-1117568
U.S. STOCKS ON THE MOVE-StoneX, US automakers, Johnson & Johnson
U.S. STOCKS ON THE MOVE-Intel, Orla Mining, Biogen
RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug
Brief: Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer
U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences